Jag Capital Management LLC Has $15.86 Million Position in Natera, Inc. $NTRA

Jag Capital Management LLC lowered its position in shares of Natera, Inc. (NASDAQ:NTRA) by 27.6% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 93,849 shares of the medical research company’s stock after selling 35,830 shares during the quarter. Natera comprises 1.8% of Jag Capital Management LLC’s holdings, making the stock its 20th biggest position. Jag Capital Management LLC’s holdings in Natera were worth $15,855,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. GAMMA Investing LLC boosted its holdings in shares of Natera by 32.3% in the 1st quarter. GAMMA Investing LLC now owns 848 shares of the medical research company’s stock valued at $120,000 after purchasing an additional 207 shares in the last quarter. Exchange Traded Concepts LLC increased its stake in shares of Natera by 15.6% in the 1st quarter. Exchange Traded Concepts LLC now owns 6,458 shares of the medical research company’s stock valued at $913,000 after acquiring an additional 871 shares in the last quarter. Precision Wealth Strategies LLC bought a new position in Natera in the first quarter worth approximately $803,000. QRG Capital Management Inc. grew its holdings in shares of Natera by 1.5% during the first quarter. QRG Capital Management Inc. now owns 5,417 shares of the medical research company’s stock valued at $766,000 after buying an additional 81 shares during the last quarter. Finally, Rakuten Securities Inc. raised its position in Natera by 117.8% in the 1st quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company’s stock valued at $31,000 after buying an additional 119 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Buying and Selling at Natera

In other Natera news, CFO Michael Burkes Brophy sold 2,491 shares of the stock in a transaction that occurred on Tuesday, September 30th. The shares were sold at an average price of $162.05, for a total value of $403,666.55. Following the transaction, the chief financial officer directly owned 69,189 shares in the company, valued at approximately $11,212,077.45. This trade represents a 3.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider John Fesko sold 678 shares of the company’s stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $155.46, for a total value of $105,401.88. Following the completion of the sale, the insider owned 152,747 shares of the company’s stock, valued at $23,746,048.62. This trade represents a 0.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 72,464 shares of company stock worth $10,963,125. 5.63% of the stock is owned by corporate insiders.

Analyst Ratings Changes

NTRA has been the subject of several research analyst reports. Cowen restated a “buy” rating on shares of Natera in a research note on Friday, August 8th. Barclays reaffirmed an “overweight” rating and issued a $210.00 price objective (up previously from $190.00) on shares of Natera in a research note on Friday, August 8th. Royal Bank Of Canada set a $268.00 target price on shares of Natera and gave the stock an “outperform” rating in a research note on Tuesday, September 2nd. Piper Sandler reiterated an “overweight” rating and issued a $220.00 price objective (up previously from $210.00) on shares of Natera in a report on Monday, August 11th. Finally, Evercore ISI raised shares of Natera to a “strong-buy” rating and set a $170.00 price target for the company in a research note on Monday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $192.88.

Natera Stock Up 2.9%

Shares of NASDAQ NTRA opened at $174.17 on Tuesday. The firm’s 50-day moving average price is $165.33 and its 200-day moving average price is $157.54. Natera, Inc. has a 52-week low of $117.27 and a 52-week high of $183.00. The company has a market cap of $23.90 billion, a PE ratio of -91.19 and a beta of 1.74.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). The company had revenue of $546.60 million during the quarter, compared to the consensus estimate of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The company’s revenue for the quarter was up 32.2% on a year-over-year basis. During the same period last year, the firm posted ($0.30) EPS. Natera has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.